Methods of treating bacterial infections using oritavancin
View Patent ↗The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.
1. A method of treating a bacterial infection in a human subject, comprising administering a therapeutically effective amount of a glycopeptide antibiotic to the human subject having the bacterial infection,
wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof,
wherein the effective amount of the glycopeptide antibiotic is between about 15 and 50 mg/kg body weight,
wherein the effective amount of the glycopeptide antibiotic provides a fraction of glycopeptide antibiotic bound to serum proteins in the subject in the range of about 50% to about 95%, and
wherein the fraction of glycopeptide antibiotic bound to serum proteins is determined from serum obtained from the subject.
2. The method of claim 1 , wherein the fraction of the glycopeptide antibiotic bound to serum proteins is in the range of about 55% to about 65%.
3. The method of claim 1 , wherein the fraction of the glycopeptide antibiotic bound to serum proteins is in the range of about 80% to about 90%.
4. The method of claim 1 , wherein the fraction of the glycopeptide antibiotic bound to serum proteins is in the range of about 70% to about 90%.
5. The method of claim 1 , wherein the fraction of glycopeptide antibiotic bound to serum proteins is determined from serum obtained from the subject about 30 minutes after completion of the administration of the glycopeptide antibiotic.
6. The method of claim 1 , wherein the fraction of glycopeptide antibiotic bound to serum proteins is determined from serum obtained from the subject about 24 hours after completion of the administration of the glycopeptide antibiotic.
7. The method of claim 1 , wherein the bacterial infection is a Complicated Skin and Skin Structure Infection (cSSSI).
8. The method of claim 1 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
9. The method of claim 1 , wherein said administering is via intravenous administration or oral administration.
10. A method of treating a bacterial infection in a subject, comprising administering a therapeutically effective amount of a glycopeptide antibiotic to the subject having, the bacterial infection, wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof, wherein the effective amount of the glycopeptide antibiotic is between about 15 and 50 mg/kg body weight, wherein the effective amount of the glycopeptide antibiotic provides a mean fraction of glycopeptide antibiotic bound to serum proteins in the subject in a range of about 50% to about 95% from a mean of about 30 minutes to about 24 hours after completion of administration of the glycopeptide antibiotic, and wherein the fraction of glycopeptide antibiotic bound to serum proteins is determined from serum obtained from the subject.
11. The method of claim 10 , wherein the fraction of the glycopeptide antibiotic bound to serum proteins is in a range of about 55% to about 65%.
12. The method of claim 10 , wherein the fraction of the glycopeptide antibiotic bound to serum proteins is in a range of about 80% to about 90%.
13. The method of claim 10 , wherein the fraction of the glycopeptide antibiotic bound to serum proteins is in a range of about 70% to about 90%.
14. The method of claim 10 , wherein the mean fraction of glycopeptide antibiotic bound to serum proteins is determined from serum obtained from the subject by calculating a mean value of nine measurements comprising:
(i) a first measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 30 minutes after completion of administration of the glycopeptide antibiotic,
(ii) a second measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 1.5 hours after completion of administration of the glycopeptide antibiotic,
(iii) a third measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 2.5 hours after completion of administration of the glycopeptide antibiotic,
(iv) a fourth measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 3.5 hours after completion of administration of the glycopeptide antibiotic,
(v) a fifth measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 4.5 hours after completion of administration of the glycopeptide antibiotic,
(vi) a sixth measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 5.5 hours after completion of administration of the glycopeptide antibiotic,
(vii) a seventh measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 6.5 hours after completion of administration of the glycopeptide antibiotic,
(viii) an eighth measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 12 hours after completion of administration of the glycopeptide antibiotic, and
(ix) a ninth measurement of a fraction of glycopeptide antibiotic bound to serum proteins determined from serum obtained from the subject at about 24 hours after completion of administration of the glycopeptide antibiotic.
15. The method of claim 10 , wherein the bacterial infection is a Complicated Skin and Skin Structure Infection (cSSSI).
16. The method of claim 10 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
17. The method of claim 10 , wherein said administering is via intravenous administration or oral administration.